• Publications
  • Influence
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.
This part of the EFISG guidelines focuses on non-neutropenic adult patients, and liposomal amphotericin B and voriconazole are supported with moderate, and fluconazole with marginal strength for the targeted initial treatment of candidaemia.
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.
Treatment duration for aspergillosis is strongly recommended based on clinical improvement, degree of immunosuppression and response on imaging, and in refractory disease, where a personalized approach considering reversal of predisposing factors, switching drug class and surgical intervention is also strongly recommended.
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.
This document reviews the available literature and provides a series of recommendations for TDM of antifungal agents.
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research
Management of mucormycosis depends on recognising disease patterns and on early diagnosis, and limited availability of contemporary treatments burdens patients in low and middle income settings.
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013.
These European Society for Clinical Microbiology and Infectious Diseases and European Confederation of Medical Mycology Joint Clinical Guidelines focus on the diagnosis and management of mucormycosis and strongly recommend continuing treatment until complete response demonstrated on imaging and permanent reversal of predisposing factors.
Changing patterns and trends in systemic fungal infections.
  • M. Richardson
  • Medicine
    The Journal of antimicrobial chemotherapy
  • 1 September 2005
Fungal opportunistic infections in persons with AIDS are no longer a major problem in developed countries, but are resulting in significant morbidity and mortality in developing countries with AIDS epidemics, and the emergence of antifungal resistance is given.
Fungal Infection: Diagnosis and Management
The author reveals how common Yeast Infections of Nails and other Cutaneous Fungal Infections are, and some of the mechanisms behind these infections, are regulated by the World Health Organization.
Changing epidemiology of systemic fungal infections.
The key elements in selecting an appropriate antifungal agent are the type of patient (solid-organ or stem-cell transplant), severity of immunosuppression, history of prolonged exposure to antIFungal drugs, and knowledge of the genera and species of the infecting pathogen and its typical susceptibility pattern.
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures.
As the mortality associated with invasive Candida infections remains high, it is important to make optimal use of available diagnostic tools to initiate antifungal therapy as early as possible and to
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.
These guidelines provide recommendations for the prevention and treatment of IC in neonates and children, which are largely extrapolated from studies performed in adults with concomitant pharmacokinetic data and models in children.